ARTICLE | Company News
Trojantec, Sellas deal
May 25, 2015 7:00 AM UTC
Trojantec granted Sellas exclusive, worldwide rights to develop and commercialize TR-1 cancer therapeutic technology and corresponding therapeutics. Trojantec will receive an upfront payment and is e...